Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q93091
UPID:
RNAS6_HUMAN
Alternative names:
-
Alternative UPACC:
Q93091
Background:
Ribonuclease K6 is a potent enzyme with a preference for the pyrimidines uridine and cytosine. It exhibits strong antibacterial activity against a wide spectrum of Gram-positive and Gram-negative bacteria, including P. aeruginosa, A. baumanii, and E. coli. This protein disrupts bacterial membrane integrity and promotes the agglutination of Gram-negative bacteria, contributing to urinary tract sterility. Notably, its bactericidal function operates independently of its RNase activity.
Therapeutic significance:
Understanding the role of Ribonuclease K6 could open doors to potential therapeutic strategies. Its broad-spectrum antibacterial efficacy and unique mechanism of action, separate from its enzymatic activity, highlight its potential as a novel antimicrobial agent.